| REGENERON |
REGENERON |
80%
|
The Company had no material revenue from these collaborations during the three months ended March 31, 2026 and 2025. |
| ALLO |
Allogene Therapeutics, Inc. |
72%
|
Reciprocal relationship from ALLO graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from ALLO g… |
| ALLO |
Allogene Therapeutics, Inc. |
72%
|
devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed by these laws or regulations, we will need to meet higher standards of data quality… |
| ALNY |
Alnylam Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from ALNY graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from ALNY g… |
| ALNY |
Alnylam Pharmaceuticals, Inc. |
72%
|
devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed by these laws or regulations, we will need to meet higher standards of data quality… |
| CRBU |
Caribou Biosciences, Inc. |
72%
|
Reciprocal relationship from CRBU graph: cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Contents Third-party payors, whether domest… |
| DTIL |
Precision BioSciences, Inc. |
72%
|
Reciprocal relationship from DTIL graph: Reciprocal relationship from NTLA graph: devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed b… |
| DTIL |
Precision BioSciences, Inc. |
72%
|
devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed by these laws or regulations, we will need to meet higher standards of data quality… |
| IONS |
Ionis Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from IONS graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from IONS graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from IONS g… |
| IONS |
Ionis Pharmaceuticals, Inc. |
72%
|
devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed by these laws or regulations, we will need to meet higher standards of data quality… |
| KALV |
KalVista Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from KALV graph: Reciprocal relationship from NTLA graph: devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed b… |
| KALV |
KalVista Pharmaceuticals, Inc. |
72%
|
devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed by these laws or regulations, we will need to meet higher standards of data quality… |
| KYTX |
Kyverna Therapeutics, Inc. |
72%
|
Reciprocal relationship from KYTX graph: certain regulatory-and clinical-related benchmarks are due to the NIH, with the minimum cumulative royalty due for a product reaching FDA approval or foreign-… |
| KYTX |
Kyverna Therapeutics, Inc. |
72%
|
. The Company had material revenue from Kyverna or ONK during the years ended December 31, 2025, 2024 or 2023. $ Other investments Restricted cash equivalents, long-term Prepaid expenses and other as… |
| MGX |
Metagenomi Therapeutics, Inc. |
72%
|
devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed by these laws or regulations, we will need to meet higher standards of data quality… |
| MGX |
Metagenomi Therapeutics, Inc. |
72%
|
Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, t… |
| PRME |
Prime Medicine, Inc. |
72%
|
Reciprocal relationship from PRME graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from PRME graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from PRME g… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
ize any potential product candidate. • Negative public opinion and increased regulatory scrutiny of CRISPR use, genome editing or gene therapy may damage public perception of the safety of our produc… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from NTLA graph: ize any potential product candidate. • Negative public opinion and increased regulatory scrutiny of CRISPR use, genom… |
| SGMO |
Sangamo Therapeutics, Inc. |
72%
|
Reciprocal relationship from SGMO graph: Reciprocal relationship from NTLA graph: devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed b… |
| SGMO |
Sangamo Therapeutics, Inc. |
72%
|
devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed by these laws or regulations, we will need to meet higher standards of data quality… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from NTLA graph: devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed … |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed by these laws or regulations, we will need to meet higher standards of data quality… |
| AVENCELL-THERAPEUTICS-INC |
AVENCELL-THERAPEUTICS-INC |
62%
|
3 and 2022. As of December 31, 2024, the Company’s investment in Kyverna is valued at $ 4.4 million . The Company recognized an unrealized loss of $ 5.6 million , recorded within “change in fair valu… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
ty-based awards, which can impact the competitiveness of our compensation. There can be no assurance that we will be successful in retaining existing personnel or recruiting new personnel. Risks Rela… |
| ONK-THERAPEUTICS-LTD |
ONK-THERAPEUTICS-LTD |
62%
|
ients who have limited or no treatment options available, with the opportunity to expand the scope of the collaboration in later phases. The Company will be responsible for the design of the editing … |
| RECODE-THERAPEUTICS-INC |
RECODE-THERAPEUTICS-INC |
62%
|
basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recove… |
| REGENERON-AGREEMENT-ATTR-CO |
REGENERON-AGREEMENT-ATTR-CO |
62%
|
any recognized $ 8.4 million and $ 7.0 million of collaboration revenue, primarily representing payments due from Regeneron pursuant to the ATTR Co/Co agreement, in the three months ended March 31, 2… |
| REWRITE-THERAPEUTICS-INC |
REWRITE-THERAPEUTICS-INC |
62%
|
itially recorded at fair value, determined according to Level 3 inputs in the fair value hierarchy described above. The SparingVision investment is included in “Investments and other assets” on the c… |
